Total Cereblon Cellular Kit
Simple, all-in-one kit for robust detection of Total Cereblon
The Cereblon binding assay is designed to screen and characterize compounds that specifically bind the E3 ligase, Cereblon.
A fast and easy way to identify new binders to Cereblon WT protein. Cereblon, also known as CRBN, is involved in many biological processes and is closely associated with proliferation, apoptosis, cell metabolism, and the occurrence of many diseases. Cereblon is also one of the two most popular E3 ligases which is recruited by bifunctional Proteolysis-targeting chimeras (PROTACs) to induce ubiquitination and subsequent proteasomal degradation of a targeted protein. Cereblon interacts with several proteins to form the functional E3 ubiquitin ligase complex, in which CRBN functions as a substrate receptor of the E3 ubiquitin ligase complex and targets proteins for proteolysis.
Identifying new Cereblon ligands is therefore a way to control biological processes involved in oncology, neurodegenerative, or metabolic diseases by inducing the proteasomal-dependent degradation of undesired proteins.
This product is also available using Alpha Technology. To learn more, visit AlphaLISA Human Cereblon binding kit webpage.
PerkinElmer has made available a range of documents with educational content and reagents dedicated to PROTAC to help you in your research. Visit our dedicated webpage to learn more.
The HTRF Cereblon binding assay is a competitive assay format which uses Thalidomide-Red as Cereblon ligand, a GST tagged human Cereblon protein, and an anti GST Cryptate-labeled antibody. Your compound competes with the Thalidomide-Red and thereby prevents FRET from occurring.
Various compounds known to be Cereblon ligands were added to the assay. Lenalidomide (assay standard), pomalidomide, and thalidomide display the right potency and pharmacological ranking in good correlation with the literature. VH032, a non-specific compound, well known as a VHL E3 ligase orthosteric ligand, and Nutlin3a, another non-specific compound, well known as a MDM2 E3 ligase orthosteric ligand, had no effect on the assay, confirming the specificity of the kit for Cereblon binders.
Various PROTAC compounds, known to be PROTAC Cereblon-ligand based, were added to the assay. BSJ-04-132, BSJ-03-123, dBRD9, TL13112, and MT802 display the right potency in good correlation with the literature. AT11 and CM1 , two non-specific compounds, well known to be PROTAC VHL-ligand based, had no effect on the assay, confirming the specificity of the kit in detecting only PROTAC Cereblon-ligand based.
Different percentages of DMSO were tested, from 0.4% to 2% (final in the wells). The results indicate that the assay window is reduced with the increasing percentages of DMSO, while the pharmacology remains stable.
Cereblon, also known as CRBN, is a ubiquitously expressed protein of 442 amino-acids (55 kDa).
CRBN interacts with DNA damage-binding protein-1 (DDB1), Cullin 4 (Cul4), and the regulator of Cullins 1 (RoC1) to form a functional E3 ubiquitin ligase complex. In this complex, CRBN functions as a substrate recognition subunit, and targets proteins for proteolysis through a ubiquitin-proteasome system (UPS). This E3 ubiquitin ligase complex can therefore achieve different cellular responses by targeting different substrates.
CRBN expression in the brain is associated with memory and learning processes. The nonsense mutation (R419X) is responsible for nonsyndromic mental retardation.
CRBN also ensures normal cell proliferation and metabolism by regulating the function of ion channels.
Cereblon is also the primary direct target of the immunomodulatory drugs (IMiDs) Thalidomide, Pomalidomide, and Lenalidomide, that are all FDA approved drugs for the treatment of multiple myeloma. These drugs induce ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN E3 ubiquitin ligase.
Easy pharmacological characterization of PPI modulators. - Technical Notes
Deciphering low- and high affinity interactions - Application Notes
Monitoring nuclear receptor binding with HTRF assays - Application Notes
Challenge large complexes with HTRF assays - Application Notes
Get the brochure about technology comparison. - Brochures
See how peer researchers challenge the viral life cycle with PPI assays - Application Notes
64BDCRBNPEG-64BDCRBNPEH - Product Insert
Latest developments on PROTAC® design and validation - Guides
Choosing the right microplate reader ensures you’ll get an optimal readout. Discover our high performance reader, or verify if your lab equipment is going to be compatible with this detection technology.Let's find your reader